- Market Size Overview
- Market Dynamics
- Segmentation Insights
- Regional Insights
- Competitive Overview
- Recent Developments
- Scope of the Report
- List of Segments Covered
- FAQs

Global Bird Flu Treatment Market Size, Share, Trends & Growth Analysis Report Segmented By Treatment Type, Route of Administration (Oral, Intravenous, Inhalational), Dosage Form, Intended Use, Patient Population, And Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), 2026-2034
Bird Flu Treatment Market Size Overview
The Bird Flu Treatment Market size was valued at USD 2.36 Billion in 2025. It is projected to grow from USD 2.48 Billion in 2026 to USD 3.72 Billion by 2034, at a CAGR of 5.20% during the forecast period.
The Bird Flu Treatment Market is witnessing significant growth due to the persistent threat of avian influenza, a viral infection that primarily affects bird species but can also impact humans. Bird flu, particularly strains like H5N1 and H7N9, has posed a global public health risk, prompting governments and health organizations to prioritize the development and distribution of effective antiviral treatments. These treatments aim to reduce mortality rates in both humans and birds, prevent transmission, and control outbreaks.
The global demand for bird flu treatments is driven by the increasing number of reported cases and outbreaks of avian influenza in regions such as Asia, Africa, and Europe. According to the World Health Organization (WHO), more than 700 human cases of H5N1 have been reported since 2003, with a mortality rate of approximately 60%. The World Organization for Animal Health (OIE) also reports ongoing bird flu outbreaks in domestic and wild birds, creating an urgent need for vaccines and antiviral medications.
The Bird Flu Treatment Market is further propelled by the advancement of therapeutic solutions, including antiviral drugs like Oseltamivir and Zanamivir, which have shown efficacy in treating avian flu infections in humans. Moreover, vaccine development has become a key area of focus, with several global pharmaceutical companies working towards creating vaccines that offer protection against various strains of the virus. Market growth is also supported by increasing awareness among governments and public health agencies, fostering investments in research, and strengthening healthcare infrastructures to combat potential pandemic risks.
Market Dynamics
Bird Flu Treatment Market Drivers
- Increasing Bird Flu Outbreaks: The recurrent avian influenza outbreaks significantly drive the Bird Flu Treatment Market. According to the World Health Organization (WHO), the H5N1 strain alone has affected over 60 countries since 2003, with millions of poultry culled to contain the spread. Such frequent outbreaks intensify the need for vaccines and antiviral treatments to prevent further infection in both birds and humans, fostering market expansion.
- Government Support and Funding for Research: Governments worldwide are increasing their investment in research and development for bird flu treatments. The U.S. Department of Health and Human Services (HHS) allocated over $200 million for the development of vaccines and antiviral drugs targeting avian influenza. This financial backing facilitates the development of more effective treatments and encourages the growth of the market.
- Rising Awareness of Public Health Risks: Public awareness of the potential threat of avian influenza has led to greater demand for preventive and therapeutic solutions. According to the Centers for Disease Control and Prevention (CDC), the heightened risk of a flu pandemic has urged governments and the healthcare industry to invest in bird flu treatment solutions, driving the market forward. This awareness is also leading to more proactive vaccination campaigns and antiviral drug distribution efforts.
- Advancements in Antiviral Drug Development: The improvement in antiviral medications, including Oseltamivir and Zanamivir, is fueling market growth. A report by the National Institutes of Health (NIH) suggests that these antiviral drugs have shown effectiveness in treating avian influenza in humans, resulting in reduced morbidity and mortality. The continuous development of more potent antiviral drugs is anticipated to further boost market demand.
- Rapid Spread of New Strains: The emergence of new, more virulent strains of avian influenza is driving the need for updated treatment options. In 2022, the OIE reported a resurgence of the H5N8 strain in Europe and Asia, prompting immediate responses in the form of vaccines and antiviral treatments. This rapid mutation underscores the necessity for innovative therapeutic solutions to keep pace with evolving viral threats.
Bird Flu Treatment Market Opportunities
- Emerging Markets Expansion: The Bird Flu Treatment Market presents significant growth opportunities in emerging economies, where the frequency of avian influenza outbreaks is increasing. For instance, the World Health Organization (WHO) reported that Southeast Asia, particularly countries like Indonesia and Vietnam, has been at the epicenter of H5N1 outbreaks. As these regions expand healthcare infrastructure, demand for antiviral treatments and vaccines is anticipated to rise (WHO).
- Increased Funding for Research and Development: Governments and international organizations are increasing funding for research into more effective bird flu treatments and vaccines. The European Commission announced a €10 million funding initiative in 2022 aimed at accelerating research into next-generation vaccines. This investment supports the development of innovative therapies, offering a promising market opportunity for pharmaceutical companies (European Commission).
- Partnerships and Collaborations Between Public and Private Sectors: Increased collaboration between governments, health organizations, and private pharmaceutical companies is creating a favorable environment for the Bird Flu Treatment Market. The U.S. National Institutes of Health (NIH) collaborates with private companies to develop vaccines and antiviral treatments. Such partnerships facilitate faster development, regulatory approvals, and market entry of new treatments, enhancing business opportunities (NIH).
- Strategic Government Stockpiling Programs: Governments are increasingly stockpiling antiviral treatments and vaccines to prepare for potential outbreaks, creating demand for these products. For instance, the U.S. government’s stockpiling program under the Department of Health and Human Services (HHS) has procured large quantities of antiviral medications like Oseltamivir. These programs provide a reliable source of demand for pharmaceutical companies (HHS).
- Focus on Vaccine Distribution Networks: As vaccine development accelerates, establishing robust vaccine distribution networks is becoming crucial. According to the World Health Organization (WHO), distributing vaccines efficiently to areas with high-risk populations is essential. Opportunities exist for companies to partner with global distribution networks and local governments to ensure rapid deployment during outbreaks, fueling market growth (WHO).
Bird Flu Treatment Market Restrain & Challenges
- High Cost of Vaccine Development: The development of effective vaccines for avian influenza can be expensive and time-consuming. The World Health Organization (WHO) reports that the cost of developing and producing a new vaccine for pandemic strains can exceed USD 1 billion, creating a financial barrier for many countries, particularly in low-resource settings. The high cost also limits the speed at which new vaccines can be developed and distributed to the global population (WHO).
- Antiviral Resistance Development: The emergence of antiviral resistance in bird flu strains presents a significant challenge to the market. For instance, the U.S. Centers for Disease Control and Prevention (CDC) has reported instances of H5N1 strains becoming resistant to commonly used antiviral drugs such as Oseltamivir. This reduces the effectiveness of current treatment options and creates a need for continuous innovation in antiviral drug development to combat resistant strains (CDC).
- Limited Accessibility in Low-Income Countries: Despite the availability of treatment options, access to bird flu treatments remains a challenge in many low-income countries. The World Health Organization (WHO) has highlighted that limited healthcare infrastructure and insufficient funding hinder the widespread availability of antiviral drugs and vaccines in these regions. This restricts the market's growth potential in some of the most affected areas (WHO).
- Regulatory Hurdles in Drug Approval: The regulatory process for approving new bird flu treatments and vaccines can be lengthy and complex. The U.S. Food and Drug Administration (FDA) has stringent requirements for clinical trials and product testing, which can delay the availability of new treatments. According to the FDA, the average time for a new drug approval process can take 10-12 years, impeding the rapid deployment of innovative solutions to combat avian influenza (FDA).
- Fluctuating Global Bird Flu Outbreaks: The unpredictable nature of bird flu outbreaks poses a challenge to the market. While avian influenza remains a global threat, the frequency and severity of outbreaks can vary. The World Health Organization (WHO) reports that, while there have been significant outbreaks, other years have seen fewer cases. This fluctuation in demand for treatment options makes it challenging for pharmaceutical companies to maintain consistent market growth (WHO).
Current Trends in the Bird Flu Treatment Market
- Advancement in Genetic-Based Therapies: Genetic-based therapies are gaining traction in the Bird Flu Treatment Market as researchers explore innovative solutions to combat avian influenza. The U.S. National Institutes of Health (NIH) reports that gene-editing techniques, such as CRISPR, are being investigated to develop treatments that target specific viral mutations. These technologies have the potential to create more personalized and effective therapies for bird flu, offering a promising alternative to traditional antiviral drugs (NIH).
- Development of Universal Influenza Vaccines: A significant trend in the Bird Flu Treatment Market is the development of universal influenza vaccines, which aim to offer broad protection against multiple strains of influenza, including avian flu. According to the World Health Organization (WHO), researchers are focusing on developing vaccines that can target common elements of influenza viruses, regardless of their strain. This would reduce the need for annual vaccine updates and improve the preparedness for future bird flu outbreaks (WHO).
- Rise of Monoclonal Antibodies for Treatment: Monoclonal antibodies are emerging as a key technology in the treatment of avian influenza. The U.S. Food and Drug Administration (FDA) has approved monoclonal antibody treatments for other viral infections, and similar approaches are being explored for bird flu. These therapies work by targeting specific components of the virus, blocking its ability to infect cells. Research and clinical trials are underway to evaluate their efficacy against various strains of bird flu (FDA).
- Integration of Artificial Intelligence for Predictive Modeling: Artificial intelligence (AI) is being used to enhance predictive modeling and forecasting of bird flu outbreaks. The U.S. Centers for Disease Control and Prevention (CDC) is leveraging AI to analyze data from animal populations and environmental conditions to predict where outbreaks are likely to occur. This technology allows for more proactive interventions, including early warnings and targeted treatment strategies, improving the global response to avian influenza (CDC).
- Increased Focus on Rapid Diagnostic Kits: There is an increasing demand for rapid diagnostic kits that can quickly identify bird flu infections, both in humans and animals. The World Health Organization (WHO) has supported the development of these kits to improve early detection, thereby reducing the spread of the virus. These diagnostics enable quicker treatment and containment measures, which are essential in managing outbreaks and minimizing the economic impact of avian influenza (WHO).
Segmentation Insights
Bird Flu Treatment Market Analysis, By Treatment Type
By Treatment Type, the market is divided into Antiviral Medications, Supportive Care, and Prophylactic Measures.
- The largest segment in the Bird Flu Treatment Market is antiviral medications, primarily consisting of drugs like Oseltamivir (Tamiflu) and Zanamivir (Relenza). These medications are crucial in treating avian influenza infections in humans, as they can reduce the severity and duration of symptoms if administered early. According to the Centers for Disease Control and Prevention (CDC), antiviral drugs like Tamiflu have been effective in treating H5N1 and H7N9 strains. The widespread use of antiviral medications during outbreaks, along with government stockpiling efforts, makes this segment dominant in the global market, especially in countries with high avian flu risks (CDC).
- Prophylactic measures are the fastest-growing segment in the Bird Flu Treatment Market, encompassing preventive strategies such as vaccines and pre-exposure antiviral prophylaxis. The World Health Organization (WHO) reports an increasing emphasis on vaccination campaigns to prevent avian flu outbreaks, particularly in regions with a history of high avian flu incidence, such as Southeast Asia. With global outbreaks causing public health alarms, countries are accelerating their vaccine distribution and prophylactic treatments, leading to this segment’s rapid growth. In 2022, the WHO launched extensive vaccination programs in countries like Indonesia and Vietnam, where avian flu outbreaks have been prevalent. This segment is crucial in reducing transmission and preventing pandemic threats (WHO).
Bird Flu Treatment Market Analysis, By Route of Administration
By Route of Administration, the market is categorized into Oral, Intravenous, and Inhalational.
- The largest segment in the Bird Flu Treatment Market is oral administration. Antiviral medications such as Oseltamivir (Tamiflu) and Zanamivir (Relenza) are predominantly administered orally, making them the preferred choice for treating avian influenza. According to the Centers for Disease Control and Prevention (CDC), oral antivirals are easy to administer and are effective when taken within 48 hours of symptom onset. This ease of use and broad accessibility make oral antivirals the leading treatment method, especially during large-scale outbreaks, where timely access to treatment is crucial (CDC).
- Inhalational administration is the fastest-growing segment, particularly for antiviral drugs such as Zanamivir, which is delivered via a nebulizer. The World Health Organization (WHO) reports that inhaled treatments are gaining traction as they provide targeted delivery to the respiratory tract, where the avian flu virus primarily affects the body. This method is preferred for severe cases, especially in hospitalized patients. The growing adoption of inhalational antiviral treatments is driven by their rapid onset of action and direct impact on viral replication in the lungs, making them a critical part of treatment strategies (WHO).
Bird Flu Treatment Market Analysis, By Dosage Form
By Dosage Form, the market is categorized into Tablets, Capsules, Solutions, and Injections.
- The largest segment in the Bird Flu Treatment Market is tablets, primarily due to the widespread use of oral antiviral medications such as Oseltamivir (Tamiflu) and Zanamivir (Relenza), which are available in tablet form. According to the Centers for Disease Control and Prevention (CDC), tablets are convenient for both outpatient and home treatment, especially during avian flu outbreaks. The accessibility and ease of storage of tablet formulations make them the most preferred choice for mass treatment campaigns and stockpiling efforts in pandemic preparedness (CDC).
- Injections are the fastest-growing segment within the Bird Flu Treatment Market. The increased demand for intravenous antiviral treatment, particularly in severe cases, is driving this trend. In patients with advanced symptoms or complications, injectable forms of antivirals such as Zanamivir provide faster and more effective delivery, especially in critical care settings. The World Health Organization (WHO) reports that injectable antivirals are essential in hospital-based care for treating severe avian flu infections, further fuelling their growth in the market (WHO).
Bird Flu Treatment Market Analysis, By Intended Use
By Intended Use, the market is categorized into Initial Treatment, Prevention, and Post-Exposure Prophylaxis.
- The largest segment in the Bird Flu Treatment Market is Initial Treatment. This includes the immediate administration of antiviral medications such as Oseltamivir (Tamiflu) and Zanamivir (Relenza) to patients showing early symptoms of avian influenza. The Centers for Disease Control and Prevention (CDC) recommends initiating antiviral treatment as soon as possible, ideally within 48 hours of symptom onset, to reduce the severity of the disease and prevent complications. Initial treatment is critical in controlling the spread of the virus and minimizing mortality, making it the dominant segment in the market (CDC).
- Post-Exposure Prophylaxis (PEP) is the fastest-growing segment in the Bird Flu Treatment Market. PEP involves the use of antiviral drugs to prevent the development of disease after exposure to the virus. The World Health Organization (WHO) has recommended antiviral treatment for individuals who have been in close contact with confirmed avian flu cases as a preventive measure. With an increasing focus on containment during outbreaks, demand for PEP has surged. According to WHO, PEP strategies are gaining importance as they can help contain outbreaks, particularly in high-risk areas such as poultry farms (WHO).
Bird Flu Treatment Market Analysis, By Patient Population
By Patient Population, the market is categorized into Adults, Pediatric, and High-Risk Individuals.
- The largest segment in the Bird Flu Treatment Market is adults, as they represent the majority of cases during avian influenza outbreaks. Adults, particularly those with underlying health conditions, are at a higher risk for developing severe complications from bird flu. According to the Centers for Disease Control and Prevention (CDC), adult populations, including healthcare workers and those in close contact with infected poultry, are more susceptible to avian flu infections. The focus on adult treatment is critical for containing outbreaks and reducing mortality rates, making this the largest segment of the market (CDC).
- The fastest-growing segment is high-risk individuals, including the elderly, pregnant women, and those with pre-existing conditions such as respiratory diseases. The World Health Organization (WHO) has emphasized that high-risk individuals are more likely to experience severe symptoms or complications from bird flu, which has led to increased demand for targeted treatment strategies. Given their vulnerability, high-risk populations are increasingly prioritized for vaccination and antiviral treatment, driving growth in this segment. The WHO reports that these groups account for a significant proportion of hospitalizations and fatalities during bird flu outbreaks (WHO).
Bird Flu Treatment Market Regional Insights
The market has been geographically analysed across five regions, Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.
- The largest region in the Bird Flu Treatment Market is Asia-Pacific, driven by the high incidence of avian influenza outbreaks in countries such as China, Indonesia, and Vietnam. The region has faced numerous bird flu epidemics over the past two decades, resulting in increased demand for effective treatment options. According to the World Health Organization (WHO), Asia-Pacific countries have experienced repeated outbreaks of avian flu, particularly the H5N1 and H7N9 strains, which have prompted governments to invest in stockpiling antiviral medications and vaccines. The large agricultural sector, particularly poultry farming, contributes to the high exposure to avian flu, creating a continuous demand for antiviral treatments. This has made Asia-Pacific the largest market for bird flu treatments. The region’s focus on preventive measures, such as vaccination campaigns and public health initiatives, is expected to drive market stability and growth in the coming years, with countries like China and India leading efforts in controlling outbreaks (WHO).
- The fastest-growing region for Bird Flu Treatment Market is the Middle East and Africa, driven by increasing surveillance and growing concerns about potential avian flu outbreaks. The World Health Organization (WHO) has reported that the Middle East, particularly Egypt, has been at the center of H5N1 outbreaks in recent years, leading to significant investments in preventive measures and antiviral treatments. Similarly, African nations are becoming more proactive in addressing avian influenza threats, creating a rapidly expanding market for bird flu treatments. With a focus on strengthening healthcare systems and increasing access to antivirals, this region is expected to witness robust growth. According to the WHO, countries like Egypt and Nigeria are focusing on surveillance and vaccination programs, helping to drive market expansion. As the threat of avian flu continues to pose a public health risk, the Middle East and Africa are prioritizing treatment accessibility, which is predicted to fuel this region's growth in the near future (WHO).
Bird Flu Treatment Market Competitive Overview
The Bird Flu Treatment Market is characterized by a competitive landscape where key pharmaceutical companies are actively engaged in the development, production, and distribution of antiviral medications, vaccines, and other treatment solutions. Prominent players in the market include Roche, GlaxoSmithKline, and AbbVie, who dominate the antiviral treatment segment with products like Tamiflu (Oseltamivir) and Relenza (Zanamivir). According to the World Health Organization (WHO), these companies have played a vital role in providing essential treatments during avian influenza outbreaks. Additionally, companies are focusing on expanding their product portfolios to address emerging strains of the virus, with innovations in antiviral drugs and vaccines being key drivers of competition. Governments worldwide, particularly in high-risk regions such as Asia-Pacific and the Middle East, are heavily involved in the procurement and distribution of these treatments to manage and prevent outbreaks. This has led to significant investments in research and development (R&D) aimed at improving the efficacy and accessibility of treatments. With rising concerns about the spread of avian flu, competition is expected to intensify, particularly in the development of next-generation antiviral solutions (CDC, WHO).
Leading Market Players in the Bird Flu Treatment Market
- Merial: Merial, a subsidiary of Boehringer Ingelheim, is a key player in the Bird Flu Treatment Market, particularly in providing vaccines for avian influenza. Known for its strong portfolio of animal health products, Merial has been instrumental in developing vaccines that help mitigate the impact of bird flu outbreaks in poultry. The company’s vaccines have been widely used in regions such as Southeast Asia, where avian influenza is a persistent threat. According to the World Health Organization (WHO), Merial’s vaccines have played a significant role in preventing the spread of H5N1 and other avian flu strains (WHO).
- Boehringer Ingelheim: Boehringer Ingelheim is a leading global provider of animal health products, including vaccines and antiviral treatments for avian influenza. The company’s comprehensive approach includes the development of preventive measures and treatment solutions for poultry. Boehringer Ingelheim’s veterinary vaccines are extensively used to control and prevent the spread of avian flu, particularly in Asia, where outbreaks have been more prevalent. According to the Centers for Disease Control and Prevention (CDC), Boehringer Ingelheim’s vaccines are critical in helping manage avian influenza, with the company being one of the key players in global pandemic preparedness (CDC).
- Zoetis: Zoetis is a prominent animal health company offering a wide range of avian influenza treatment and prevention solutions. Specializing in vaccines and pharmaceutical products, Zoetis focuses on enhancing poultry health and managing viral infections like avian flu. Their products are vital in controlling outbreaks, especially in regions such as North America and Europe, where commercial poultry farming is a major industry. Zoetis has made significant contributions to the development of vaccines that address both H5N1 and H7N9 strains of avian flu. The World Health Organization (WHO) highlights Zoetis as a key player in pandemic prevention efforts (WHO).
Top Strategies Followed by Players
- Research and Development of Vaccines: One of the top strategies followed by key players like Boehringer Ingelheim and Merial is the continuous investment in research and development (R&D) to create more effective vaccines for avian influenza. These companies focus on developing vaccines that can address a broad spectrum of avian flu strains, such as H5N1 and H7N9. According to the World Health Organization (WHO), these efforts are crucial in preventing the spread of bird flu and protecting poultry populations in high-risk areas. By prioritizing R&D, these players aim to stay ahead of evolving virus strains and maintain their competitive advantage in the market (WHO).
- Partnerships and Collaborations with Governments: Another key strategy employed by companies such as Zoetis and Merck Animal Health is forming partnerships and collaborations with governments and international organizations. These collaborations are essential for securing government contracts for the supply of vaccines and antiviral treatments during avian influenza outbreaks. By working closely with government agencies like the Centers for Disease Control and Prevention (CDC) and the WHO, these companies can quickly respond to outbreaks and ensure timely distribution of their products. This strategy enhances their market presence and strengthens their role in global pandemic preparedness (CDC).
- Expansion into Emerging Markets: To tap into high-growth opportunities, leading players like Zoetis and Elanco Animal Health focus on expanding their presence in emerging markets, particularly in regions such as Asia-Pacific, Latin America, and Africa. These markets have seen an increase in avian influenza outbreaks, driving demand for bird flu treatments. By expanding their distribution networks and local manufacturing capabilities, these companies can effectively cater to the rising demand for poultry health solutions. According to the World Health Organization (WHO), such expansion strategies are vital for controlling outbreaks and enhancing market penetration in regions most affected by avian flu (WHO).
List of Companies Profiled in the Report are
- Merial
- Boehringer Ingelheim
- Phibro Animal Health
- Novartis Animal Health
- Intervet Inc
- Sanofi Pasteur SA
- Zoetis
- Ceva Animal Health
- Merck Animal Health
- Elanco Animal Health
Global Bird Flu Treatment Market Report Scope and Key Segmentation
| Attributes | Report Details |
| 2025 Market Size | USD 2.36 Billion |
| 2026 Market Size | USD 2.48 Billion |
| 2034 Revenue Forecast | USD 3.72 Billion |
| Growth Rate | 5.20% from 2026-2034 |
| Study Period | 2026-2034 |
| Units Used | USD Billion |
| Key Segments | By Treatment Type
By Route of Administration
By Dosage Form
By Intended Use
By Patient Population
|
| Geographical Coverage |
|
| Companies Profiled |
*No particular order has been followed while listing the company names. *List of companies to be profiled in the report can be customized. |
List of Segments Covered
This section of the Bird Flu Treatment Market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Treatment Type
- Antiviral Medications
- Supportive Care
- Prophylactic Measures
By Route of Administration
- Oral
- Intravenous
- Inhalational
By Dosage Form
- Tablets
- Capsules
- Solutions
- Injections
By Intended Use
- Initial Treatment
- Prevention
- Post-Exposure Prophylaxis
By Patient Population
- Adults
- Pediatric
- High-Risk Individuals
Frequently Asked Questions (FAQs) about this Report
How big is the Global Bird Flu Treatment market?
What is the Global Bird Flu Treatment market growth?
Which country holds the highest share in the Global Bird Flu Treatment market?
How is the Global Bird Flu Treatment market segmented in the report?
Who are the key players in the Global Bird Flu Treatment market?
Author

Chitra Patil
Senior Market Research Analyst – Healthcare & Life Sciences
Chitra Patil is a market research professional with over 7+ years of experience in the Healthcare & Life Sciences industry. She specializes in delivering comprehensive market intelligence across diverse healthcare segments, including Healthcare Services, Healthcare IT, Medical Devices, Pharmaceuticals, Biotechnology, and Animal Nutrition and Wellness. Her work focuses on identifying emerging trends, evaluating market dynamics, and providing actionable insights that support strategic business decisions in regulated healthcare environments. Her professional responsibilities include market sizing, growth forecasting, demand analysis, competitive intelligence, and evaluation of technological innovations in healthcare delivery systems and life sciences products. She has successfully contributed to the development of multiple healthcare-focused research studies that support manufacturers, healthcare providers, technology firms, and pharmaceutical stakeholders.
Read more about Chitra PatilCOMPANY
CONTACT
UG-203, Gera Imperium Rise, Wipro Circle Metro Station, Hinjawadi, Pune - 411057
- sales@valuemarketresearch.com
- +1-888-294-1147
BUSINESS HOURS
Monday to Friday : 9 A.M IST to 6 P.M IST
Saturday-Sunday : Closed
Email Support : 24 x 7
© , All Rights Reserved, Value Market Research